What is the efficacy of preexposure prophylaxis (PrEP) in the prevention of HIV infection?

Updated: Jul 01, 2019
  • Author: Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg (Truvada) has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults. Daily emtricitabine/tenofovir is one prevention option that is part of the general guidelines for HIV prevention. For more information, see Preexposure HIV Prophylaxis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!